Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep60 | Adrenal cortex (to include Cushing's) | ECE2017

Treatment of patients with primary and secondary adrenal insufficiency with hydrocortisone modified-release (Plenadren®)

Pilli Tania , Forleo Raffaella , Cardinale Sandro , Cenci Valeria , Pacini Furio

Introduction: Adrenal insufficiency is a life-threatening disease. Conventional treatment requires multiple daily doses of immediate-release hydrocortisone or cortisone acetate causing non-physiological peaks and nadir of cortisol and it has been also associated with premature mortality, high frequency of infections, reduced quality of life, altered metabolic profile and reduced bone mineral density. A modified-release hydrocortisone (Plenadren®, Shire) by combining a rap...